IMpower133, a foundational study, demonstrated the initial and critical benefit of adding atezolizumab, a PD-L1 inhibitor, to standard platinum–etoposide chemotherapy in the first-line setting for ES-SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.